Covalent Gets Contract for Atherosclerosis Trial

Covalent Group has signed a $1.7 million contract for a Phase II trial assessing the potential benefit of aggressive anti-microbial therapy in inhibiting progression of atherosclerosis in subjects with known vascular disease. Atherosclerosis is a disease affecting the arterial blood vessels throughout the body.

The trial will utilize data recorded from serial images obtained with multiple medical imaging techniques. The imaging data will be analyzed in with clinical assessments and biomarkers of inflammation to assess the efficacy of the study drug. Covalent will provide consulting services on trial design and protocol development, project and study site management, field operations, data management, biostatistical support, and medical writing.

Kenneth M. Borow, M.D., Covalent Group’s president and chief executive officer, commented, “We are delighted to have been chosen by this new client to work on its proof-of-concept Phase II trial involving an innovative approach to altering the natural history of atherosclerosis. The program combines our proven expertise in clinical trial design and operational services, our well-known expertise in cardiovascular disease, and our extensive experience using multiple medical imaging techniques to assess drug efficacy in subjects at high risk for clinical events. We anticipate a long and mutually beneficial relationship with the sponsoring company.”